These provide strong evidence to support the IL-33/ST2 axis as an oncogenic driver of GC progression, that acts via unidirectional signaling between gastric epithelium and immune compartment to establish an immunosuppressive and pro-tumorigenic microenvironment. Here, IL33 is linked to gastric cancer.